Autori
Badiani B, Chiumente M, Messori A.

Topic
Analisi statistiche e metanalisi

Rivista
Eur J Obstet Gynecol Reprod Biol

Impact factor
1,868

Abstract
OBJECTIVES: The aim of this study was to evaluate the pharmacoeconomic profile in Italy of preoperative treatment with ulipristal acetate at the dose of 5 mg/day for 13 weeks in comparison with placebo prior to surgical management of symptomatic uterine fibroids.

STUDY DESIGN: The pharmacoeconomic analysis was based on the calculation of incremental cost-effectiveness ratio (ICER). Effectiveness data were derived from the randomized-controlled trial PEARL-1, whilst costs data were retrieved from the published literature. A Markov model was employed to simulate the pattern of costs and two univariate sensitivity analyses tested the robustness of the results.

RESULTS: In comparison with placebo, ulipristal acetate 5 mg for presurgical therapy was estimated to be associated with an incremental cost of €351 per patient. Costs per patient were €3836 for ulipristal acetate vs €3485 for placebo. The incremental effectiveness was 0.01931 QALYs per patient (around 7 quality-adjusted days per patient). Hence, the cost effectiveness ratio was calculated to be €18,177 per QALY gained.

CONCLUSIONS: Preoperative use of ulipristal acetate 5 mg in patients with uterine fibroids has a favorable pharmacoeconomic profile.

Link PubMed del paper
https://pubmed.ncbi.nlm.nih.gov/29408752/